Drug Profile


Alternative Names: FRG 8813; loctidine; Protecadin; Stogar

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fujirebio
  • Developer Boryung Pharmaceutical; Taiho Pharmaceutical
  • Class Acetamides; Antiulcers; Cytoprotectives; Gastric antisecretories; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Histamine H2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric ulcer; Gastritis; Peptic ulcer; Reflux oesophagitis
  • Discontinued Inflammatory bowel diseases

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 Nov 2015 Boryung completes phase I clinical trials for Peptic ulcer in South Korea (PO) (NCT02581696)
  • 01 Oct 2015 Phase-I clinical trials in Peptic ulcer in South Korea (PO) (NCT02581696)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top